.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,758,813

« Back to Dashboard

Claims for Patent: 8,758,813

Title:Abuse-deterrent drug formulations
Abstract: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. In one embodiment, the drug is modified to increase its lipophilicity by forming a salt between the drug and one or more fatty acids wherein the concentration of the one or more fatty acids is one to 15 times the molar amount of the active agent. The abuse-deterrent composition prevents the immediate release of a substantial portion of drug, even if the physical integrity of the formulation is compromised and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is broken down or dissolved gradually within the GI tract by a combination of enzymatic degradation, surfactant action of bile acids, and mechanical erosion.
Inventor(s): Hirsh; Jane (Wellesley, MA), Fleming; Alison (Mansfield, MA), Rariy; Roman (Philadelphia, PA), Klibanov; Alexander M. (Boston, MA)
Assignee: Collegium Pharmaceutical, Inc. (Canton, MA)
Application Number:13/870,690
Patent Claims: 1. A method for the management of pain comprising administering to a patient in need thereof a therapeutically effective pharmaceutical composition comprising solid microparticles, wherein the microparticles comprise: a) an active agent, b) one or more fatty acids, and c) one or more carrier materials selected from the group consisting of waxes or wax-like substances and mixtures thereof; wherein the active agent comprises a fatty acid salt of oxycodone, and the one or more fatty acids are present in an amount ranging from 6.9 to 15 times the molar amount of the active agent.

2. The method of claim 1, wherein the molar concentration of the one or more fatty acids in the microparticle is 6.9 to 10 times the molar amount of the active agent.

3. The method of claim 1, wherein the one or more fatty acids is one or more C.sub.5 to C.sub.30 monovalent fatty acids, one or more C.sub.8 to C.sub.40 divalent fatty acids, or mixtures thereof.

4. The method of claim 2 wherein the one or more fatty acids is one or more C.sub.5 to C.sub.30 monovalent fatty acids, one or more C.sub.8 to C.sub.40 divalent fatty acids, or mixtures thereof.

5. The method of claim 3, wherein the one or more fatty acids is one or more C.sub.5 to C.sub.30 monovalent fatty acids selected from the group consisting of pentanoic acid, hexanoic (caproic) acid, heptanoic acid, octanoic (carylic) acid, nonanoic acid, decanoic (capric) acid, undecanoic acid, dodecanoic (lauric) acid, tridecanoic acid, tetradecanoic (myristic) acid, pentadecanoic acid, hexadecanoic (palmitic) acid, heptadecanoic (margaric) acid, octadecanoic (stearic) acid, nonadecanoic acid, eicosanoic (arachidic) acid, heneicosanoic acid, docasanoic (behenic) acid, tricosanoic acid, tetracosanoic (lignoceric) acid, pentacosanoic acid, hexacosanoic acid, heptacosanoic acid, octacosanoic acid, nonacosanoic acid, triacontanoic acid, linoleic acid, oleic acid, and mixtures thereof.

6. The method of claim 4, wherein the one or more fatty acids is one or more C.sub.5 to C.sub.30 monovalent fatty acids selected from the group consisting of pentanoic acid, hexanoic (caproic) acid, heptanoic acid, octanoic (carylic) acid, nonanoic acid, decanoic (capric) acid, undecanoic acid, dodecanoic (lauric) acid, tridecanoic acid, tetradecanoic (myristic) acid, pentadecanoic acid, hexadecanoic (palmitic) acid, heptadecanoic (margaric) acid, octadecanoic (stearic) acid, nonadecanoic acid, eicosanoic (arachidic) acid, heneicosanoic acid, docasanoic (behenic) acid, tricosanoic acid, tetracosanoic (lignoceric) acid, pentacosanoic acid, hexacosanoic acid, heptacosanoic acid, octacosanoic acid, nonacosanoic acid, triacontanoic acid, linoleic acid, oleic acid, and mixtures thereof.

7. The method of claim 5, wherein the one or more fatty acids is myristic acid.

8. The method of claim 6, wherein the one or more fatty acids is myristic acid.

9. The method of claim 1, wherein the one or more carrier materials are present in an amount of from 0.25 to 8 times the weight of the amount of active agent.

10. The method of claim 2, wherein the one or more carrier materials are present in an amount of from 0.25 to 8 times the weight of the amount of active agent.

11. The method of claim 9, wherein the one or more carrier materials are present in an amount of from 2 to 6 times by weight of the amount of active agent.

12. The method of claim 10, wherein the one or more carrier materials are present in an amount of from 2 to 6 times by weight of the amount of active agent.

13. The method of claim 1, wherein the carrier material is a wax selected from the group consisting of carnauba wax, beeswax, microcrystalline wax, and mixtures thereof.

14. The method of claim 2, wherein the carrier material is a wax selected from the group consisting of carnauba wax, beeswax, microcrystalline wax, and mixtures thereof.

15. The method of claim 13, wherein the carrier material is a mixture of beeswax and carnauba wax.

16. The method of claim 14, wherein the carrier material is a mixture of beeswax and carnauba wax.

17. The method of claim 1, wherein the active agent comprises a myristic acid salt of oxycodone, the one or more fatty acids is myristic acid, and the carrier comprises beeswax and carnauba wax.

18. The method of claim 2, wherein the active agent comprises a myristic acid salt of oxycodone, the one or more fatty acids is myristic acid, and the carrier comprises beeswax and carnauba wax.

19. The method of claim 1, wherein the active agent is prepared by contacting a molar excess of one of the one or more fatty acids with the free base form of the active agent.

20. The method of claim 2, wherein the active agent is prepared by contacting a molar excess of one of the one or more fatty acids with the free base form of the active agent.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc